Shanghai, China & Brussels, Belgium - August 10, 2022 - Full-Life Technologies Co., Ltd. (“Full-Life”) today announced two key appointments to its Radioisotope Technology leadership team and the establishment of a Radioisotope Technology Advisory Board.

Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform.

Ravi Chari, Ph.D., appointed Chief Scientific Officer Julie Wu appointed Chief Financial Officer, Philippe van Put appointed General Manager, Europe Lanny Sun appointed Chairman.

Nuclear Medicine has seen a renaissance in recent years with significant clinical and commercial validation in some of the most challenging cancers.